IT industry body Nasscom and state-run Biotechnology Industry Research Assistance Council (BIRAC) on Monday launched a contest, JANCare, to develop technology solutions for delivery of health care solutions in small towns and rural areas.
The contest aims to identify up to 25 best healthtech solutions from start-ups and small and medium enterprises (SMEs) and provide pilot test beds in collaboration with state governments at primary health centres (PHCs), community health centres (CHCs), and industry to help their validation and scale up for adoption. Department of Biotechnology Secretary Renu Swarup said the 25 innovations will help in testing waters to deliver healthcare service to the last mile in rural areas.
She said more than the financial support, the involvement of state governments with PHCs and CHCs for test beds is more important to boost the confidence in new technology based solutions. "The population of low resource areas; PHCs, CHCs in rural and semi-urban areas are likely to get benefitted through local deployment of the innovative and affordable healthtech solutions. This innovation challenge would promote customized products developed by start-ups and SMEs to address the local challenges and unmet needs," Swarup said.
AstraZeneca, GE Healthcare, Siemens Healthineers, Medanta Hospitals, St. John's Research Institute, Health Care Global Enterprises and Tata AIG have joined hands with this innovation challenge to provide their support and mentorship to the participating start-ups till the end of pilot phase. Medanta Chairman and Managing Director Naresh Trehan said about 17 per cent of super-specialist are Indians.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
"We are running whole world healthcare systems, except we did not look inwards. It gives me great pleasure and actually it gives me a boost in my own thinking that the vision that we set out many years ago is going to be multiplied by with this partnership," Trehan said. Nasscom President Debjani Ghosh said good and affordable healthcare should be available to everyone, and with this vision in mind Nasscom has been instrumental in helping build a tech enabled healthcare start-up ecosystem in the country."Through this JANCare Innovation Grand Challenge, we aim to evangelise more organisations and individuals to build specialised healthcare solutions, and democratise access to modern medicine for all," Ghosh said.